PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively
Summary
BOSTON--( BUSINESS WIRE )--PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.PAREXEL Biotech builds on the Company’s heritage of clinical, regulatory, commercial and technology expertise with enhanced strategic consulting and asset development capabilities, offering a new Biotech-focused team and organizational structure for customers.Graciela Racaro added, “We look forward to combining PAREXEL’s expertise and global infrastructure with an agile and efficient delivery model that is aligned to this specific segment, enabling emerging biotech companies to focus on their core capabilities and reach their strategic goals.”“To build on our commitment to biotech success, we have grown our capabilities to include management and strategy consulting, pipeline development, value substantiation and evidence vetting.We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services.